Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Axitinib

5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity

RADIATION

Radiation Therapy

45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy

Trial Locations (1)

45267-0502

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Cincinnati

OTHER

NCT01508117 - Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | Biotech Hunter | Biotech Hunter